In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

Joseph Young Biography and Net Worth

CAO of Vera Therapeutics

Before joining Vera, Mr. Young was Senior Vice President of Finance at Plexxikon Inc., where he served in positions of increasing responsibility during a 14-year tenure and led the accounting and finance operations supporting the company’s sale to Daiichi Sankyo for nearly $1 billion in 2011. Post-merger, he continued to oversee accounting and finance, as well as other business functions for Plexxikon, and was a member of the management team during a period in which two of the company’s drugs were approved and launched in oncology indications. Prior to Plexxikon, Mr. Young was a member of the finance teams at Cerus Corporation (Nasdaq: CERS) and VaxGen, Inc. Mr. Young began his career as an auditor for Ernst & Young LLP.

He received an MBA from UC Berkeley, Haas School of Business, and a BA from UCLA. He is a certified public accountant (inactive status).

What is Joseph R. Young's net worth?: The estimated net worth of Joseph R. Young is at least $2.53 million as of April 10th, 2024. Mr. Young owns 53,171 shares of Vera Therapeutics stock worth more than $2,528,281 as of November 5th. This net worth estimate does not reflect any other assets that Mr. Young may own. Learn More about Joseph R. Young's net worth.
How old is Joseph R. Young?: Mr. Young is currently 51 years old. There are 5 older executives and no younger executives at Vera Therapeutics. The oldest executive at Vera Therapeutics is Dr. Robert M. Brenner M.D., Chief Medical Officer, who is 56 years old. Learn More on Joseph R. Young's age.
How do I contact Joseph R. Young?: The corporate mailing address for Mr. Young and other Vera Therapeutics executives is , , . Vera Therapeutics can also be reached via phone at 650-770-0077 and via email at [email protected]. Learn More on Joseph R. Young's contact information.
Has Joseph R. Young been buying or selling shares of Vera Therapeutics?: Joseph R. Young has not been actively trading shares of Vera Therapeutics over the course of the past ninety days. Most recently, Joseph R. Young sold 5,714 shares of the business's stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a transaction totalling $228,560.00. Following the completion of the sale, the senior vice president now directly owns 53,171 shares of the company's stock, valued at $2,126,840. Learn More on Joseph R. Young's trading history.
Who are Vera Therapeutics' active insiders?: Vera Therapeutics' insider roster includes Marshall Fordyce (Founder), and Joseph Young (CAO). Learn More on Vera Therapeutics' active insiders.
Are insiders buying or selling shares of Vera Therapeutics?: In the last year, Vera Therapeutics insiders bought shares 1 times. They purchased a total of 161,290 shares worth more than $4,999,990.00. In the last year, insiders at the sold shares 12 times. They sold a total of 1,680,949 shares worth more than $44,809,507.61. The most recent insider tranaction occured on October, 28th when Director Beth C Seidenberg sold 15,000 shares worth more than $720,450.00. Insiders at Vera Therapeutics own 21.7% of the company. Learn More about insider trades at Vera Therapeutics.
Information on this page was last updated on 10/28/2024.

Joseph R. Young Insider Trading History at Vera Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/10/2024	Sell	5,714	$40.00	$228,560.00	53,171

Joseph R. Young Buying and Selling Activity at Vera Therapeutics

Vera Therapeutics Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Today's Range

Now: $47.70

$44.94

$48.00

50 Day Range

MA: $40.65

$35.66

$47.34

2 Week Range

Now: $47.70

$9.88

$50.78

Volume

843,649 shs

Average Volume

910,195 shs

Market Capitalization

$2.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad